SCHEMBL2174816

SCHEMBL2174816

COC(=O)c1ccc(CNC(=O)CN(c2ccccc2OC)S(=O)(=O)c2ccc(F)cc2)cc1

nearest known ligand 0.60

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.57
MAPT P10636 3/20 0.57
MEN1 O00255 2/20 0.57
KMT2A Q03164 2/20 0.57
PTGER1 P34995 4/20 0.57
RORC P51449 1/20 0.56
PSEN1 P49768 1/20 0.55
PSEN2 P49810 1/20 0.55
APH1B Q8WW43 1/20 0.55
NCSTN Q92542 1/20 0.55
APH1A Q96BI3 1/20 0.55
PSENEN Q9NZ42 1/20 0.55
TP53 P04637 1/20 0.53
ATM Q13315 1/20 0.53
CNR2 P34972 1/20 0.52
GAA P10253 2/20 0.52
ALDH1A1 P00352 1/20 0.51
NPSR1 Q6W5P4 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2174886 0.79 RORC (0.55) SMN1; SMN2MAPTMEN1KMT2APTGER1
SCHEMBL2176323 0.78 RORC (0.63) MEN1KMT2APTGER1RORC
SCHEMBL18101489 0.78 SMN1; SMN2 (0.70) SMN1; SMN2MAPTTP53ALDH1A1NPSR1
SCHEMBL12407143 0.77 MAPT (0.56) SMN1; SMN2MAPTMEN1KMT2APTGER1
SCHEMBL12407765 0.76 PTGER1 (0.66) SMN1; SMN2MAPTMEN1KMT2APTGER1
SCHEMBL15672565 0.76 RORC (0.61) SMN1; SMN2MAPTMEN1KMT2APTGER1
SCHEMBL13894273 0.76 PTGER1 (0.63) SMN1; SMN2MAPTMEN1KMT2APTGER1
SCHEMBL12487551 0.76 PTGER1 (0.61) PTGER1RORCTP53
SCHEMBL8714947 0.76 ESR1 (0.63) SMN1; SMN2MAPTMEN1KMT2AALDH1A1
SCHEMBL12407282 0.74 PTGER1 (0.63) PTGER1RORC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090312328-A1 SULFONAMIDE COMPOUND OR SALT THEREOF ASTELLAS PHARMA INC. (JP) 2009-12-17 US claimed
EP-2050446-A1 SULFONAMIDE COMPOUND OR SALT THEREOF Astellas Pharma Inc. (JP) 2009-04-22 EP claimed
EP-2050446-B1 SULFONAMIDE COMPOUND OR SALT THEREOF ASTELLAS PHARMA INC (JP) 2014-05-07 EP disclosed
US-7973078-B2 Sulfonamide compound or salt thereof ASTELLAS PHARMA INC. (JP) 2011-07-05 US disclosed
US-20090312328-A1 SULFONAMIDE COMPOUND OR SALT THEREOF ASTELLAS PHARMA INC. (JP) 2009-12-17 US disclosed
EP-2050446-A1 SULFONAMIDE COMPOUND OR SALT THEREOF Astellas Pharma Inc. (JP) 2009-04-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090312328-A1 SULFONAMIDE COMPOUND OR SALT THEREOF PTGER1, CYSLTR1, PTGER2 SMN1; SMN2 731/4885MAPT 4297/4885MEN1 3347/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.